Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 161,972 |
|
|||||
| News | - | ||||||
| Day High | 9.78 | Low High |
|||||
| Day Low | 9.22 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Shattuck Labs Inc | STTK | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.24 | 2.58% | 9.54 | 13:24:44 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 9.30 | 9.22 | 9.78 | 9.30 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,241 | 161,972 | $ 9.39 | $ 1,520,659 | - | 1.3301 - 11.11 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:28:58 | 1 | $ 9.515 | USD |
Shattuck Labs Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 452.91M | 47.47M | - | 1.66M | -87.3M | -1.84 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Shattuck Labs News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical STTK Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 8.89 | 10.31 | 8.85 | 9.72 | 385,723 | 0.65 | 7.31% |
| 1 Month | 9.22 | 10.31 | 8.56 | 9.39 | 272,846 | 0.32 | 3.47% |
| 3 Months | 9.75 | 11.11 | 8.06 | 9.25 | 333,404 | -0.21 | -2.15% |
| 6 Months | 1.46 | 11.11 | 1.41 | 6.36 | 979,680 | 8.08 | 553.42% |
| 1 Year | 2.94 | 11.11 | 1.3301 | 6.23 | 508,186 | 6.60 | 224.49% |
| 3 Years | 30.25 | 38.90 | 1.3301 | 8.34 | 282,026 | -20.71 | -68.46% |
| 5 Years | 18.61 | 60.5162 | 1.3301 | 11.12 | 266,439 | -9.07 | -48.74% |
Shattuck Labs Description
| Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor. |
